Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site




REGENERON PHARMACEUTICALS, INC. (REGN)

The QuantWave forecast for REGN regeneron pharmaceuticals, inc.

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions. Founded in 1988, the company has a strong track record of bringing novel drugs to market, particularly in the fields of ophthalmology, immunology, and oncology. Regeneron is known for its revolutionary antibody-based treatment technologies, which have led to the development of breakthrough therapies. The company is committed to improving patient outcomes by constantly reinvesting in research and development. With a team of talented scientists and cutting-edge technology, Regeneron is at the forefront of the pharmaceutical industry.
The graph shows the results of our forecasting system for REGN. You can view historical price data with some markers indicating where our system has been signaling and where the projected targets have been achieved. This demonstrates to what extent our system's forecasts have been justified in real market conditions.

We do not display all the achieved goals on the graph, you can get detailed information about the achieved goals in the corresponding section on this page

Access the REGN Forecast by QuantWave

Stock ticker: REGN
Name: REGENERON PHARMACEUTICALS, INC.
Sector: Healthcare
Investing Risk: MEDIUM
Forecast length: 6 days
Accuracy: 67.33 %
Average profit per target: 14.56 %


REGN Achieves Targets with Precision, as Predicted by QuantWave

Show news about the achieved forecast
Signal Date Signal Price Date Reached Price Reached Profit Direction
2022-07-01593.76 $2025-05-30490.28 $ 17.43%
2022-08-04613.26 $2022-10-13750.49 $ 22.38%
2024-05-07967.3 $2024-08-131155.14 $ 19.42%
2024-05-14981.93 $2024-08-151172.09 $ 19.37%
2024-05-21991.21 $2024-08-151172.09 $ 18.25%
2024-05-28970.48 $2024-08-131155.14 $ 19.03%
2024-10-081002.49 $2024-10-31835.89 $ 16.62%
2024-10-151013.73 $2024-10-31835.89 $ 17.54%
2025-01-14688.97 $2025-04-04572.6 $ 16.89%
2025-01-21685.9 $2025-04-04572.6 $ 16.52%
2025-01-23692.73 $2025-04-04572.6 $ 17.34%
2025-02-04695.13 $2025-04-04572.6 $ 17.63%
2025-02-11663.63 $2025-04-10545.58 $ 17.79%
2025-02-20694.99 $2025-04-08555.99 $ 20%
2025-02-21699.3 $2025-04-08555.99 $ 20.49%
2025-02-25722.4 $2025-04-08555.99 $ 23.04%
2025-02-26705.9 $2025-05-09527 $ 25.34%
2025-02-27701.74 $2025-05-09527 $ 24.9%
2025-02-28697.71 $2025-05-09527 $ 24.47%
2025-02-28697.71 $2025-05-30490.28 $ 29.73%
2025-03-04674.49 $2025-05-30490.28 $ 27.31%
2025-03-07706.47 $2025-05-30490.28 $ 30.6%
2025-03-10743.73 $2025-05-30490.28 $ 34.08%
2025-03-14665.89 $2025-06-04484.93 $ 27.18%
2025-03-21657.51 $2025-06-04484.93 $ 26.25%
2025-03-21657.51 $2025-06-04484.93 $ 26.25%
2025-04-01616.09 $2025-05-30490.28 $ 20.42%
2025-04-02624.68 $2025-05-30490.28 $ 21.51%

Access the REGN Forecast by QuantWave


The latest news about the achievement of forecasting results and global news about regeneron pharmaceuticals, inc.


REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....

REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with a Profit of 30.6%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit of 30.6% for investors who followed the short signal....




Other QuantWave offers: